로딩 중…
StockDiggingStockDigging

SyntekaBio, Inc.

226330· KOSDAQ
₩1,828+0.33%
2026-06-19

Price Chart

SyntekaBio, Inc.-71.70%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap44.34B KRW
Revenue2.98B KRW
Net Income-207.4M KRW
Total Assets43.69B KRW
Net Assets28.34B KRW
Employees61
Value
P/B1.56x
P/S14.87x
FCF Yield-24.04%
Profitability
ROE-0.73%
ROA-0.47%
Op. Margin-379.27%
Revenue Growth-51.39%
Financial Health
Debt Ratio154.18%
Total Debt7.77B KRW
FCF-10.66B KRW
Cash13.40B KRW
Current Ratio1.16x
Performance
1Y Return-71.70%
1M Return-22.21%
From 52W High-73.84%
1Y MDD-73.80%
Trading
Volume147,278 shares
Foreign Own.1.57%
Per Share
EPS-690 KRW
BPS1,168 KRW

Company Info

CEO 정종선
Employees 61
Founded 2009
HQ 대전광역시 유성구, KR

Syntekabio, a bio venture established in 2009, became a research institute company in 2014, receiving dedicated supercomputing technology for genetic testing from ETRI. It offers AI new drug development platform services and a genomic big data platform, including NGS-ARS® precision medicine services, on a cloud basis. Leveraging an AI platform that integrates supercomputing and genomic big data technologies, Syntekabio focuses on innovating the new drug development process and developing new paradigm treatments. The company is headquartered in Yuseong-gu, Daejeon Metropolitan City.